[
  {
    "company_name": "Amgen Inc.",
    "symbol": "AMGN",
    "overall_sentiment": "positive",
    "financials": {
      "revenue_growth": "+22%",
      "outlook_summary": "On track to meet 2024 full goals and long-term objectives with a strong growth outlook."
    },
    "executives": [
      {
        "name": "Robert Bradway",
        "role": "CEO",
        "sentiment": "positive"
      },
      {
        "name": "Justin Claeys",
        "role": "Not specified",
        "sentiment": "neutral"
      },
      {
        "name": "James Bradner",
        "role": "Not specified",
        "sentiment": "positive"
      },
      {
        "name": "Murdo Gordon",
        "role": "Not specified",
        "sentiment": "positive"
      },
      {
        "name": "Vikram Karnani",
        "role": "Not specified",
        "sentiment": "positive"
      },
      {
        "name": "Peter Griffith",
        "role": "Not specified",
        "sentiment": "positive"
      }
    ],
    "technologies": [
      {
        "technology_name": "MariTide",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "ongoing",
        "profit_outlook": "high potential",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "James Bradner"
      },
      {
        "technology_name": "Repatha",
        "technology_sentiment": "positive",
        "investment_action": "maintaining",
        "investment_horizon": "ongoing",
        "profit_outlook": "moderate potential",
        "rd_investment": "unclear",
        "revenue_impact": "+double-digit volume growth",
        "mentioned_by": "Murdo Gordon"
      },
      {
        "technology_name": "EVENITY",
        "technology_sentiment": "positive",
        "investment_action": "maintaining",
        "investment_horizon": "ongoing",
        "profit_outlook": "moderate potential",
        "rd_investment": "unclear",
        "revenue_impact": "+double-digit volume growth",
        "mentioned_by": "Murdo Gordon"
      },
      {
        "technology_name": "TEZSPIRE",
        "technology_sentiment": "positive",
        "investment_action": "maintaining",
        "investment_horizon": "ongoing",
        "profit_outlook": "moderate potential",
        "rd_investment": "unclear",
        "revenue_impact": "+double-digit volume growth",
        "mentioned_by": "Murdo Gordon"
      },
      {
        "technology_name": "TAVNEOS",
        "technology_sentiment": "positive",
        "investment_action": "maintaining",
        "investment_horizon": "ongoing",
        "profit_outlook": "moderate potential",
        "rd_investment": "unclear",
        "revenue_impact": "+double-digit volume growth",
        "mentioned_by": "Murdo Gordon"
      },
      {
        "technology_name": "BLINCYTO",
        "technology_sentiment": "positive",
        "investment_action": "maintaining",
        "investment_horizon": "ongoing",
        "profit_outlook": "moderate potential",
        "rd_investment": "unclear",
        "revenue_impact": "+double-digit volume growth",
        "mentioned_by": "Murdo Gordon"
      },
      {
        "technology_name": "Legacy Horizon Business",
        "technology_sentiment": "positive",
        "investment_action": "integrating",
        "investment_horizon": "ongoing",
        "profit_outlook": "moderate potential",
        "rd_investment": "unclear",
        "revenue_impact": "$914 million in Q1",
        "mentioned_by": "Murdo Gordon"
      },
      {
        "technology_name": "TEPEZZA",
        "technology_sentiment": "positive",
        "investment_action": "maintaining",
        "investment_horizon": "ongoing",
        "profit_outlook": "moderate potential",
        "rd_investment": "unclear",
        "revenue_impact": "+5%",
        "mentioned_by": "Vikram Karnani"
      },
      {
        "technology_name": "Obesity",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "long-term",
        "profit_outlook": "high potential",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "Robert Bradway"
      },
      {
        "technology_name": "Tarlatamab",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "ongoing",
        "profit_outlook": "high potential",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "Jay Olson"
      },
      {
        "technology_name": "Small Cell Lung Cancer",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "ongoing",
        "profit_outlook": "high potential",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "Murdo Gordon"
      },
      {
        "technology_name": "GLP-1s",
        "technology_sentiment": "neutral",
        "investment_action": "unclear",
        "investment_horizon": "unclear",
        "profit_outlook": "unclear",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "Mohit Bansal"
      },
      {
        "technology_name": "AMG 133",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "long-term",
        "profit_outlook": "high potential",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "Mohit Bansal"
      },
      {
        "technology_name": "Obesity and Cardiometabolic Strategy",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "long-term",
        "profit_outlook": "high potential",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "Gregory Renza"
      }
    ],
    "year": 2024,
    "quarter": 1,
    "date": "2024-05-01 22:45:00"
  },
  {
    "company_name": "Amgen Inc.",
    "symbol": "AMGN",
    "overall_sentiment": "positive",
    "financials": {
      "rd_investment_change": "expected to increase to $1.3 billion in 2024 from $1.1 billion to $1.2 billion",
      "outlook_summary": "Long-term outlook remains robust. Expenses for Q3 expected to grow at a similar rate to Q1 and Q2. OI&E expected to be approximately $2.5 billion, including interest expense related to the Horizon acquisition debt. Non-GAAP tax rate expected to be in the 15% to 16% range.",
      "eps_change": "unclear"
    },
    "executives": [
      {
        "name": "Justin Claeys",
        "role": "Vice President of Investor Relations",
        "sentiment": "neutral"
      },
      {
        "name": "Bob Bradway",
        "role": "CEO",
        "sentiment": "positive"
      },
      {
        "name": "Peter Griffith",
        "role": "CFO",
        "sentiment": "positive"
      },
      {
        "name": "Murdo Gordon",
        "role": "EVP Global Commercial Operations",
        "sentiment": "neutral"
      },
      {
        "name": "Vikram Karnani",
        "role": "EVP of Human Resources",
        "sentiment": "positive"
      },
      {
        "name": "Jay Bradner",
        "role": "Chief Scientific Officer",
        "sentiment": "neutral"
      }
    ],
    "technologies": [
      {
        "technology_name": "rare disease products",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "ongoing",
        "profit_outlook": "high potential",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "Bob Bradway"
      },
      {
        "technology_name": "MariTide manufacturing",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "ongoing",
        "profit_outlook": "unclear",
        "rd_investment": "1.3 billion USD",
        "revenue_impact": "unclear",
        "mentioned_by": "Peter Griffith"
      },
      {
        "technology_name": "TEPEZZA",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "ongoing",
        "profit_outlook": "high potential",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "Gary Nachman"
      }
    ],
    "year": 2024,
    "quarter": 2,
    "date": "2024-08-06 16:30:00"
  },
  {
    "company_name": "Amgen Inc.",
    "symbol": "AMGN",
    "overall_sentiment": "positive",
    "financials": {
      "rd_investment_change": "up 35% quarter-over-quarter to the prior year",
      "outlook_summary": "Capital expenditure guidance remains at $1.3 billion for 2024. Long-term growth outlook remains strong.",
      "oi_and_e_guidance": "$2.4 billion to $2.5 billion",
      "non_gaap_tax_rate": "14% to 15% range",
      "capital_expenditure_guidance": "$1.3 billion for 2024"
    },
    "executives": [
      {
        "name": "Justin Claeys",
        "role": "Vice President of Investor Relations",
        "sentiment": "neutral"
      },
      {
        "name": "Bob Bradway",
        "role": "CEO",
        "sentiment": "positive"
      },
      {
        "name": "Murdo Gordon",
        "role": "Executive",
        "sentiment": "positive"
      },
      {
        "name": "Vikram Karnani",
        "role": "Executive",
        "sentiment": "neutral"
      },
      {
        "name": "James Bradner",
        "role": "Executive",
        "sentiment": "positive"
      },
      {
        "name": "Peter Griffith",
        "role": "Executive",
        "sentiment": "positive"
      }
    ],
    "technologies": [
      {
        "technology_name": "MariTide",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "ongoing",
        "profit_outlook": "high potential",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "James Bradner"
      },
      {
        "technology_name": "Obesity treatments",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "long-term",
        "profit_outlook": "high potential",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "James Bradner"
      },
      {
        "technology_name": "513",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "ongoing",
        "profit_outlook": "high potential",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "James Bradner"
      },
      {
        "technology_name": "TEPEZZA",
        "technology_sentiment": "positive",
        "investment_action": "maintaining",
        "investment_horizon": "ongoing",
        "profit_outlook": "moderate potential",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "James Bradner"
      },
      {
        "technology_name": "Antibody platform",
        "technology_sentiment": "positive",
        "investment_action": "maintaining",
        "investment_horizon": "ongoing",
        "profit_outlook": "moderate potential",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "Robert Bradway"
      },
      {
        "technology_name": "MVASI",
        "technology_sentiment": "positive",
        "investment_action": "maintaining",
        "investment_horizon": "ongoing",
        "profit_outlook": "moderate potential",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "Murdo Gordon"
      },
      {
        "technology_name": "PAVBLU",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "ongoing",
        "profit_outlook": "high potential",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "Murdo Gordon"
      }
    ],
    "year": 2024,
    "quarter": 3,
    "date": "2024-10-30 16:30:00"
  },
  {
    "company_name": "Amgen Inc.",
    "symbol": "AMGN",
    "overall_sentiment": "positive",
    "financials": {
      "outlook_summary": "Expects continued growth and innovation through 2030 and beyond, driven by a strong business, portfolio, and pipeline. Anticipates operating margin of roughly 46% in 2025, with Q1 operating margin lowest at roughly 42% and accelerating thereafter. Non-GAAP OI&E expected at approximately $2.4 billion in 2025. Non-GAAP tax rate expected at 15% to 16%. Share repurchases not to exceed $500 million in 2025. Share count in Q1 2025 expected flat to Q4 2024. Capital expenditures of approximately $2.3 billion in 2025. Free cash flow performance in 2025 expected to be similar to 2023, impacted by working capital timing, tax payments, and repatriation tax payment.",
      "revenue_growth": "mid-single-digit percent level (over past decade)",
      "eps_change": "approximately 9% per year (over past decade)",
      "rd_investment_change": "Declining non-GAAP SG&A spend as a percentage of product sales by approximately 1 to 2 percentage points year-over-year in 2025."
    },
    "executives": [
      {
        "name": "Justin Claeys",
        "role": "Vice President of Investor Relations",
        "sentiment": "neutral"
      },
      {
        "name": "Robert Bradway",
        "role": "CEO",
        "sentiment": "positive"
      },
      {
        "name": "Jay Bradner",
        "role": "Head of R&D",
        "sentiment": "positive"
      },
      {
        "name": "Murdo Gordon",
        "role": "Head of Commercial",
        "sentiment": "positive"
      },
      {
        "name": "Peter Griffith",
        "role": "CFO",
        "sentiment": "positive"
      }
    ],
    "technologies": [
      {
        "technology_name": "Automation",
        "technology_sentiment": "positive",
        "investment_action": "maintaining",
        "investment_horizon": "ongoing",
        "profit_outlook": "unclear",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "Peter Griffith"
      },
      {
        "technology_name": "Artificial Intelligence",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "ongoing",
        "profit_outlook": "high potential",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "Jay Bradner"
      }
    ],
    "year": 2024,
    "quarter": 4,
    "date": "2025-02-04 16:30:00"
  }
]